Compugen Ltd (Nasdaq: CGEN) disclosed results from recent studies further confirming CGEN-15049 as a promising target candidate for cancer immunotherapy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE